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Recent studies have shown that B cell deple-
tion therapy (BCDT) can efficiently reduce 
disease progression in relapsing-remitting mul-
tiple sclerosis (RR-MS) and in experimental 
autoimmune encephalomyelitis (EAE; Bar-Or 
et al., 2008; Hauser et al., 2008; Matsushita et al., 
2008). Thus, in addition to their documented 
regulatory capacity (Mauri et al., 2003; Mann 
et al., 2007; Fillatreau et al., 2008; Lampropoulou 
et al., 2008), B cells also promote the inflam-
matory response in EAE and MS (Anderton 
and Fillatreau, 2008; Lampropoulou et al., 
2010). RR-MS is a chronic inflammatory de-
myelinating disease of the central nervous sys-
tem (CNS) associated with an accumulation of 
immune cells at lesion sites. Although poly-
morphisms in genes controlling T cell activa-
tion show the strongest association with disease 
susceptibility (Oksenberg et al., 2008), B cell 
activation is also a common abnormality in 
RR-MS, highlighted by the presence of intra-
thecal oligoclonal immunoglobulin bands in 
>90% of patients (Fillatreau and Anderton, 
2007). It is therefore clear that B cells partici-
pate in this disease. However, the mechanisms 
by which B cells exert pathogenic effects in 
RR-MS are not understood.
B cells might promote tissue destruction 
through autoantibody production in RR-MS 
(Wekerle, 1999). Myelin-reactive autoantibodies 
are sometimes found in serum and CNS of RR-
MS patients, and transfusion of autoantibody-
containing serum exacerbates demyelination 
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B cells have paradoxical roles in autoimmunity, exerting both pathogenic and protective 
effects. Pathogenesis may be antibody independent, as B cell depletion therapy (BCDT) 
leads to amelioration of disease irrespective of autoantibody ablation. However, the mecha-
nisms of pathogenesis are poorly understood. We demonstrate that BCDT alleviates central 
nervous system autoimmunity through ablation of IL-6–secreting pathogenic B cells. B cells 
from mice with experimental autoimmune encephalomyelitis (EAE) secreted elevated levels 
of IL-6 compared with B cells from naive controls, and mice with a B cell–specific IL-6 
deficiency showed less severe disease than mice with wild-type B cells. Moreover, BCDT 
ameliorated EAE only in mice with IL-6–sufficient B cells. This mechanism of pathogenesis 
may also operate in multiple sclerosis (MS) because B cells from MS patients produced 
more IL-6 than B cells from healthy controls, and this abnormality was normalized with  
B cell reconstitution after Rituximab treatment. This suggests that BCDT improved disease 
progression, at least partly, by eliminating IL-6–producing B cells in MS patients. Taking 
these data together, we conclude that IL-6 secretion is a major mechanism of B cell–driven 
pathogenesis in T cell–mediated autoimmune disease such as EAE and MS.
© 2012 Barr et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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In RR-MS, the disease-promoting activity of B cells might 
be related to a stimulatory effect on pathogenic T cells (Cross 
et al., 2006). We therefore tested if B cells could modulate 
T cell responses through IL-6. Naive T cells were stimulated in 
vitro in the presence of supernatants from B cells activated with 
LPS+CD40. Remarkably, T cell proliferation was significantly 
enhanced by supernatants from WT B cells (even though they 
were diluted at least fivefold) but not from IL-6–deficient 
B cells (Fig. 1 B; P = 0.0053 by two-way ANOVA). We next 
evaluated the capacity of various B cell subsets to secrete IL-6. 
Marginal zone (MZ), follicular (FO), and transitional (TN) 
B cell subsets were sorted by flow cytometric sorting based on 
expression of CD19, CD21, CD23, and CD1d. MZ B cells 
(CD21HiCD23Lo or CD1dHi) rapidly secreted IL-6 in response 
to TLR4 stimulation with LPS, and the amount of IL-6 pro-
duced was further increased to 4 ng/ml by provision of surro-
gate T cell help, in the form of anti-CD40 (Fig. 1 C). Intriguingly, 
this same subset also secreted the greatest amounts of IL-10, as 
we have reported previously (Barr et al., 2007; Lampropoulou 
et al., 2008; Fig. 1 C), although it is noteworthy that the signals 
driving maximal levels of these cytokines are distinct (i.e., IL-6 
with CpG and IL-10 with LPS). The difference in IL-6 produc-
tion by various B cell subsets was less apparent in longer term 
cultures (72 h stimulation; unpublished data).
To investigate whether B cells might contribute to EAE 
pathogenesis—which is T cell mediated—through production 
of IL-6, we first sought to determine if IL-6 production by 
B cells was increased during EAE. CD19+ B cells were isolated 
from naive mice, and from mice with EAE by magnetic and 
FACS sorting. IL-6 mRNA was expressed at significantly 
higher levels in B cells from EAE mice compared with B cells 
from naive animals (Fig. 1 D; P = 0.035 by Student’s t test). 
Given our demonstration that MZ/CD1dHi B cells represent 
the most significant source of B cell–derived IL-6, we next 
assessed the composition of the B cell compartment during the 
EAE response. The frequency of MZ B cells in EAE mice was 
elevated from day 14 onwards (Fig. 1 E). To assess the capacity 
of individual subsets to produce IL-6 in EAE, mRNA was 
quantified on FACS-sorted samples. Increased IL-6 mRNA 
expression was most noticeable in MZ (CD21HiCD23Lo; 
P = 0.0244) and TN (CD21LoCD23Lo; P = 0.024) but not in 
FO (CD21IntCD23Hi) B cell subsets (Fig. 1 F). Thus, both fre-
quency of IL-6 producers and capacity of these subsets to pro-
duce IL-6 are elevated in EAE. As with naive mice (Fig. 1 A), 
B cells from EAE mice were found to be the major source of 
IL-6 in responses to TLR stimulation, as whole cell cultures 
from CD20-depleted animals with EAE showed up to 86% re-
duction in IL-6 secretion (Fig. 1 G). Increased IL-6 production 
by B cells is not restricted to CNS autoimmunity. B cells 
from mice immunized with a nonpathogenic peptide antigen 
(chicken egg OVA, pOVA) in complete Freund’s adjuvant 
showed similarly increased IL-6 secretion (unpublished data). 
We have also previously shown that B cells secrete elevated 
IL-6 during Salmonella infection (Barr et al., 2010). Thus, it ap-
pears that B cells respond via innate receptors rather than via 
antigen-specific BCR. Indeed, stimulation of B cells from myelin 
and axonal loss in rats (Zhou et al., 2006). However, clinical 
improvement in patients treated with Rituximab often 
precedes reduction in autoantibody levels (Edwards and 
Cambridge, 2006; Martin and Chan, 2006). More importantly, 
treatment with Atacicept, which reduces numbers of short- 
and long-lived plasma cells (Balázs et al., 2002; O’Connor 
et al., 2004; Belnoue et al., 2008), resulted in aggravation, not 
improvement, of RR-MS (Hartung and Kieseier, 2010). 
These observations concur to indicate that B cells propagate 
this autoimmune disease via antibody-independent mecha-
nisms. If antibody is not the principal mediator of B cell patho-
genesis, then we must ask what other aspects of B cell function 
are important? Rituximab treatment results in a noticeable 
decline of T cell numbers in CNS of treated patients (Cross 
et al., 2006), suggesting that B cells facilitate RR-MS progres-
sion by sustaining pathogenic T cell responses, possibly through 
presentation of antigen and/or secretion of cytokines (Bar-Or 
et al., 2010). The latter mechanism attracted our interest 
because cytokine blockade is often an effective treatment for 
autoimmune disease (Bar-Or et al., 2010). Furthermore, cyto-
kines can be elicited from B cells irrespective of antigenic 
specificity (e.g., toll-like receptor [TLR]–activated B cells, 
microbe-specific B cells, or B cells reactive to other antigens). 
Antigen presentation to encephalitogenic T cells, in contrast, 
can be performed only by myelin-specific B cells. This is a 
highly pertinent consideration because an important propor-
tion of the B cell response is not myelin reactive in RR-MS 
(Owens et al., 2009). A candidate cytokine for the pathogenic 
functions of B cells in RR-MS is IL-6, which is essential for 
the development of EAE (Eugster et al., 1998; Mendel et al., 
1998; Okuda et al., 1998; Samoilova et al., 1998), the primary 
mouse model of RR-MS. B cells can secrete large amounts of 
IL-6 in response to polyclonal activating stimuli and subse-
quently enhance T cell proliferation in vitro (Lampropoulou 
et al., 2008) and Th17 responses in vivo (Barr et al., 2010), 
which have a pathogenic role in autoimmune disease (Korn 
et al., 2009). Based on this rationale, we evaluated the role of 
IL-6 production by B cells in EAE and MS.
RESULTS
B cells are a major source of IL-6,  
which is stimulatory for T cells
We first sought to determine the relative contribution of 
B cells to total IL-6 production in vivo. To address this, naive 
mice were ablated of B cells using anti-CD20. Whole (un-
sorted) spleen and lymph node cell cultures were then stimulated 
with LPS, CpG, and anti-CD40, which engage major recep-
tors involved in activation of APCs. Anti-CD20 therapy 
depleted B cells with 95% or greater efficiency, with the 
knock-on consequence of enriching innate APC and T cells 
in the cultures (unpublished data). Despite this enrichment in 
many potential sources of IL-6 (e.g., macrophages, dendritic 
cells, neutrophils, and T cells), IL-6 production was massively 
reduced after anti-CD20 depletion (Fig. 1 A), and B cells ac-
counted for 65–95% of IL-6, and, therefore, appeared to be a 
major source of IL-6 in secondary lymphoid tissues.
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generated mixed bone marrow chimeric mice with a B cell–
specific deficiency in IL-6 production (B-IL-6/), together 
with control chimeras (B-WT). The validation of these chi-
meras is outlined in Fig. 2 A. Of note, B-IL-6/ mice con-
tain a 20% IL-6 deficiency in all hematopoietic cells, in 
addition to a complete lack of IL-6 production by B cells. To 
control for the effect that such deficiency outside the B cell 
compartment could have on the disease course, we generated 
IL-620% chimeras, which have 20% IL-6 deficiency in all 
hematopoietic compartments, including in B cells. After 8–10 
wk of reconstitution, chimeric mice were immunized with 
MOG to induce EAE. All groups of mice started to display 
disease signs with similar kinetics (mean day of disease onset 
oligodendrocyte glycoprotein (MOG) or OVA-immunized mice 
does not produce IL-6 when restimulated with antigen, either 
alone or in conjunction with anti-CD40 (unpublished data). 
Collectively, our data show that B cells are an important source 
of IL-6 when cells from secondary lymphoid organs are exposed 
to stimuli controlling activation of immunity, and IL-6 from 
B cells can significantly increase T cell responses in vitro. Further-
more, IL-6 production by B cells is increased during EAE.
Mice with a B cell–specific IL-6 deficiency  
develop an attenuated form of EAE
We next asked whether IL-6 production by B cells contrib-
uted to disease pathogenesis during EAE. To this end, we 
Figure 1. B cells from naive and EAE 
mice are a major source of IL-6 which 
stimulates T cells in vitro. (A) Whole spleno-
cyte and lymph node cells were isolated from 
mice after B cell depletion or isotype control 
treatment. IL-6 levels were quantified by ELISA 
after 72 h of stimulation with LPS, CpG, and/or 
anti-CD40. Bars represent the mean of groups 
of five mice and are representative of two 
independent experiments. (B) Supernatants 
from LPS- and anti-CD40–treated WT B cells, 
IL-6/ B cells, or cell-free controls were 
added to sorted CD4+ T cells in the presence of 
anti-CD3 and anti-CD28. Proliferation was 
determined by thymidine incorporation after 
72 h. Data points represent the means of trip-
licate cultures of cells pooled from two mice, 
with error bars the SEM. Results are represen-
tative of two independent experiments. Statis-
tical analysis is by two-way ANOVA, where **, 
P < 0.01. (C) B cell subsets were isolated from 
spleens of naive mice by magnetic and FACS 
sorting based on CD19, CD21, CD23, and CD1d 
expression. After in vitro stimulation for 24 h 
with LPS and/or anti-CD40, IL-6 (top) and  
IL-10 (bottom) levels in supernatants were quan-
tified by Bioplex. Histograms represent mean 
cytokine production from triplicate cultures of 
cells pooled from four to eight mice. Error bars 
represent SEM. Comparison between subsets 
stimulated with LPS and CD40 is by Student’s  
t test; MZ versus FO, P = 0.0156 and CD1dHi 
versus CD1dLo, P = 0.0352. Data presented are 
combined from nine independent experiments. 
(D) RT-PCR for IL-6 mRNA was performed on 
pooled B cells sorted directly ex vivo from 
naive and EAE (at day 14) mice. Data presented 
is combined from two independent experi-
ments. Histograms represent mean mRNA 
expression from triplicate samples obtained from pooled cells from 10 mice. Error bars represent SEM. Statistical analysis is by Student’s t test, where *, P < 0.05. 
(E) Kinetics of B cell subset expansion during EAE were assessed by flow cytometry. Each point represents the mean of 6–12 mice, with error bars the SEM. 
Data are representative of two separate experiments. (F) RT-PCR for IL-6 mRNA was performed on sorted B cell subsets as indicated. Data presented is com-
bined from two independent experiments. Comparisons between naive and EAE B cells for each subset was statistically analyzed by Student’s t test, where 
NS, P > 0.05 and *, P < 0.05. (G) Splenocyte and draining lymph node cells were isolated from EAE mice (at day 14) after treatment with isotype control or 
anti-CD20 at day 10. IL-6 was quantified Bioplex on supernatants after 72 h of stimulation with LPS, CpG, and anti-CD40. Bars represent the mean on 
duplicate samples pooled from five mice and are representative of three independent experiments.
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when comparing global disease burdens. In such compari-
son, IL-620% mice also displayed a slightly milder overall 
disease than B-WT mice (P < 0.001), but the difference was 
clearly stronger for B-IL-6/ mice (P < 0.001 B-IL-6/ 
vs. B-WT, P < 0.001 B-IL-6/ vs. IL-620%), indicating that 
lack of IL-6 production by B cells was the major cause of 
B-WT = 9.2 ± 0.3, B-IL-6/ = 9.0 ± 0.3, and IL-620% = 
8.5 ± 0.3), indicating that IL-6 production by B cells was 
not required for initiation of the pathogenic process. How-
ever, B-IL-6/ mice showed a markedly lower maximal 
disease score than control groups (B-IL-6/ = 3.8 ± 0.2, 
IL-620% = 4.8 ± 0.3, and B-WT = 5.1 ± 0.3), implying 
that B cells drive disease exacerbation through the produc-
tion of IL-6. Reflecting this, fewer B-IL-6/ mice reached 
a disease severity imposing sacrifice (because of ethical 
regulations) compared with B-WT or IL-620% mice (P = 
0.0077 and P = 0.1830, respectively; Fig. 2 C). In addi-
tion, B-IL-6/ mice showed a better recovery from dis-
ease than the two control groups (Fig. 2 B). B-IL-6/ mice 
also appeared to suffer a less severe EAE than B-WT mice 
Figure 2. Mice with a B cell–specific IL-6 deficiency develop an 
attenuated form of EAE. (A) Splenic B cells (left) and non–B cells (right) 
from B-WT, B-IL-6/, and IL-620% chimeric mice were MACS sorted and 
cultured for 72 h with PMA and ionomycin. Levels of IL-6 were then quanti-
fied by ELISA. Histograms represent the mean of triplicate cultures on 
pooled cells from 5–10 mice, with error bars indicating SEM. Data presented 
is representative of five separate experiments. (B) EAE progression was 
monitored for 32 d after immunization with MOG in B-WT, B-IL-6/, and 
IL-620% chimeric mice. Each point represents the mean disease score and 
error bars represent SEM. Statistical analysis is by two-way ANOVA, where 
***, P < 0.001, compared with B-WT mice. (C) Survival curves of chimeric 
mice after induction of EAE. Statistical analysis by log-rank test where NS,  
P > 0.05 and **, P < 0.01. Data presented is combined from three independent 
experiments (B-WT, n = 27; B-IL-6/, n = 27; and IL-620%, n = 15).
Figure 3. BCDT is effective only in mice with IL-6–sufficient B cells, 
irrespective of MOG-reactive antibody levels. (A) Clinical EAE scores of  
B-WT, IL-620%, and B-IL-6/ chimeras after anti-CD20 depletion after disease 
onset (day 10). Curves represent the mean disease scores, with errors bars 
indicating SEM. Statistical analysis was done by two-way ANOVA, where NS,  
P > 0.05 and ***, P < 0.001. (B) MOG-specific antibody was quantified by ELISA. 
Each point represents antibody titer from individual mice, with the bar indicat-
ing the mean. Statistical analysis is by Student’s t test, where NS, P > 0.05. Data 
presented is combined from two independent experiments (n = 6–12).
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antibody responses in 
isotype control and 
anti-CD20–treated 
animals. Total MOG-
specific antibody lev-
els were similarly 
reduced in all the 
groups of chimeras treated with anti-CD20, irrespective of 
improvement of disease outcome (Fig. 3 B). This applied to 
all detectable antibody isotypes (IgG1 and IgM; unpublished 
data). From these results, we conclude that BCDT in mice 
acts through abrogating IL-6 production by B cells. The B cell 
IL-6–dependent mechanism of pathogenesis was unrelated 
to antibody production because mice with WT or IL-6–
deficient B cells produced similar amounts of MOG-reactive 
antibodies during EAE.
Ameliorated EAE in B-IL-6/ chimeras is associated  
with a reduced Th17 response
IL-6 has a critical role for the maintenance of Th17 cells 
(Korn et al., 2009), a T cell subset implicated in pathogenesis 
of EAE (Bettelli et al., 2006). We tested the impact of IL-6 
disease attenuation in B-IL-6/ mice. Collectively, our re-
sults show that B cells specifically exacerbate ongoing disease 
through IL-6 production.
BCDT acts by eliminating IL-6 production by B cells, 
irrespective of its effects on MOG-reactive antibodies
B cells might contribute to autoimmune pathogenesis via 
several mechanisms, in addition to IL-6 secretion, including 
through production of antibodies or other inflammatory 
cytokines. To test the importance of IL-6 production in 
the pathogenic functions of B cells during EAE, we treated 
B-IL-6/ and B-WT chimeric mice with a B cell–depleting 
anti-CD20 antibody after initiation of disease. As previ-
ously described (Matsushita et al., 2008), such anti-CD20 
treatment resulted in a marked amelioration of disease in 
mice with WT B cells (Fig. 3 A; B-WT, P < 0.0001; IL-620%, 
P < 0.0001). We then asked if this effect was related to 
the elimination of IL-6 production by B cells by treating 
B-IL-6/ mice with anti-CD20 (Fig. 3 A). Remarkably, 
depletion of B cells had no impact on disease severity in 
B-IL-6/ chimeras, suggesting that BCDT works primarily 
by eliminating IL-6–producing B cells. We then measured 
Figure 4. Ameliorated EAE in B-IL-6/ 
chimeras is associated with impaired Th17 
responses in vivo. (A) Representative FACS 
plots showing frequencies of IL-17 and IFN-–
secreting T cells by intracellular staining 32 d 
after MOG-induced EAE. (B) Combined data 
from two EAE experiments showing frequen-
cies of IL-17–(left) and IFN- (right)–producing 
T cells by intracellular cytokine staining. Each 
point represents an individual mouse (n = 5–13), 
with the bar indicating the mean. Significance 
was determined by one-way ANOVA with  
Bonferroni’s post-testing, where NS, P > 0.05 
and *, P < 0.05. (C) IL-17 and IFN- secretion by 
CD4+ splenic T cells from B-WT and B-IL-6/ 
chimeric mice (at 32 d after EAE induction). 
Cytokines were quantified by ELISA after 3 d of 
culture with varying concentrations of MOG in 
the presence of WT irradiated APC. Curves rep-
resent the mean cytokine level with errors bars 
indicating SEM. Statistical analysis was by two-
way ANOVA comparing B-WT with B-IL-6/, 
where NS, P > 0.05 and **, P < 0.01. Data pre-
sented is combined from two separate experi-
ments and is representative of four independent 
experiments. (D) Transcription factor expression 
by circulating CD4+ T cells at day 14 after in-
duction for RORt, Tbet, and FoxP3. Each sym-
bol represents an individual mouse, with the 
bar indicating the mean (n = 7–8), with data 
representative of two independent experi-
ments. Statistical analysis is by Student’s t test, 
where ***, P < 0.001; **, P < 0.01, and NS,  
P > 0.05. (E) Frequencies of IL-17– and IFN-–
secreting DO11.10 T cells were determined  
by intracellular staining 5 d after transfer and 
immunization of WT and JHD (B cell deficient) 
hosts. Each point represents an individual 
mouse (n = 5), with the bar indicating the 
mean. Significance was determined by  
Student’s t test where NS, P < 0.05 and  
***, P < 0.001. Data presented is representative 
of two independent experiments.
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pre-Rtx vs. post-Rtx, P = 0.0349; pre-Rtx vs. HC, P = 
0.0185; post-Rtx vs. HC, P = 0.1763). Finally, we tested IL-17 
production in PBMC from RR-MS patients depleted of 
B cells or not, and found, in accordance with our EAE studies, 
that B cell depletion lead to a reduced IL-17 response with-
out having an impact on IFN- production (Fig. 5 C; IL-17, 
P = 0.0400; IFN-, P = 0.7104). Collectively, these data 
suggest that, as in EAE, B cells contribute to pathogenesis of 
RR-MS through production of IL-6.
DISCUSSION
In the clinic, BCDT can markedly ameliorate the course of 
autoimmune diseases in patients, but the mechanisms under-
lying these beneficial effects are poorly understood, as they are 
thought, in many cases, to operate irrespective of autoanti-
body levels. Here, we demonstrate that IL-6 production is the 
major mechanism of B cell–mediated pathogenesis during 
EAE, and we show that this inflammatory pathway is mark-
edly increased in RR-MS patients. Autoantibody levels were 
unaffected by IL-6 production by B cells. This is the first 
demonstration of a nonantibody-mediated mechanism of 
B cell pathogenesis in EAE and MS. Remarkably, the elevated 
production by B cells on the Th17 response during EAE. 
Intracellular cytokine staining of spleen cells from mice with 
EAE ex vivo revealed a significantly impaired IL-17 produc-
tion by T cells in B-IL-6/ mice, compared with B-WT 
controls (Fig. 4, A and B; P = 0.0236), whereas IFN- secre-
tion was unaffected. The reduction in IL-17 expression was 
not complete, indicating that other cells and factors also con-
tributed to Th17 polarization in this model, besides IL-6–
producing B cells. In addition to ex vivo intracellular 
cytokine, we also restimulated purified splenic CD4+ T cells 
from EAE mice with MOG in the presence of WT irradiated 
APC. In agreement with the ex vivo data, T cells from 
B-IL-6/ mice secreted less IL-17 than those from B-WT 
chimeras, whereas levels of IFN- were equivalent (Fig. 4 C; 
P = 0.0094). Given the modest reduction in IL-17 produc-
tion by CD4+ T cells in B-IL-6/ mice, we also quantified 
ex vivo expression of the Th17 master regulator RORt by 
intracellular staining on circulating CD4+ T cells. In accor-
dance with the secretion of IL-17 by splenic T cells, expres-
sion of RORt was significantly reduced in B-IL-6/ 
chimeras (Fig. 4 D). Intriguingly, Tbet expression was also 
impaired, whereas FoxP3 expression was not. This effect on 
T cell IL-17 production was noticeable systemically, in the 
spleen and in the blood. Although there was a trend toward 
reduced Th17 cells, numbers in the CNS and draining LN of 
B-WT and B-IL-6/ mice at the peak of disease (day 14), 
and upon recovery (day 32) were not statistically different 
(unpublished data). We then asked if B cells also promoted 
Th17 responses in response to a distinct non–self-antigen 
such as OVA. For this purpose, transgenic OVA-specific 
DO11.10 CD4+ T cells were adoptively transferred into WT 
or B cell–deficient JHD hosts, and IL-17 expression by antigen- 
reactive CD4+ T cells was measured by flow cytometry after 
immunization with OVA. In agreement with the data ob-
tained with MOG, DO11.10 T cell expression of IL-17 was 
greatly impaired in B cell-deficient mice, whereas IFN- was 
not affected (Fig. 4 E; P = 0.0017). Collectively, these data 
reveal that IL-6–producing B cells have an essential role in 
the propagation of Th17 responses in vivo, which might 
exacerbate CNS pathogenesis during EAE.
B cells from RR-MS patients secrete elevated levels  
of IL-6, which is normalized after BCDT
In our final series of experiments, we investigated the rele-
vance of our findings on IL-6 production by B cells in EAE 
for the corresponding human disease, namely RR-MS. To 
achieve this, we isolated peripheral blood B cells from 
patients with RR-MS and healthy controls. After stimulation 
in vitro by engagement of BCR and CD40, with or without 
CpG DNA, IL-6 was quantified by ELISA. We found that 
B cells from RR-MS patients secreted IL-6 at four- to five-
fold higher levels than B cells from healthy controls (Fig. 5 A; 
P = 0.0275). In a separate longitudinal study of RR-MS patients 
before and after BCDT with Rituximab, we found that 
B cells returning after depletion secreted reduced levels of 
IL-6, comparable with the healthy control group (Fig. 5 B; 
Figure 5. B cells from patients with MS secrete elevated levels  
of IL-6, which is reduced after BCDT. (A) IL-6 production by B cells 
isolated from MS patients and healthy controls after in vitro stimulation. 
B cells were isolated ex vivo and stimulated by engagement of BCR and 
CD40 with or without addition of TLR9 ligand (CpG DNA) for 3 d and  
supernatants were harvested for cytokine analysis by ELISA. (B) Longitudinal 
study showing IL-6 production from B cells from MS patients before and 
after Rituximab treatment. Patients were given two infusions of 1,000 mg 
Rituximab, 2 wk apart and then followed prospectively. The data shown 
was obtained from CD19+ B cells isolated from PBMC obtained from the 
patients before treatment with Rituximab and at 12 mo after treatment, 
after in vitro stimulation via BCR, CD40, and TLR9. (C) IL-17 (left) and  
IFN- (right) production by whole PBMCs from RR-MS patients or PBMCs 
from the same individuals depleted of B cells. Data presented is from 8  
(A) and 12 MS patients or sex- and age-matched healthy controls (B and 
C), with bars representing the mean and error bars SEM. Statistical analy-
sis is by Mann-Whitney U test, where NS, P > 0.05 and *, P < 0.05.
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response has been reset. As memory B cells have been reported 
to secrete elevated levels of IL-6 (Burdin et al., 1995; Good 
et al., 2006; Cognasse et al., 2008), a speculative interpreta-
tion would be that alleviation of disease by BCDT is asso-
ciated with depletion of these cells. The phenotype and 
repopulation kinetics of this patient cohort have been previ-
ously published, and they show that the B cells reemerging 
after BCDT are almost exclusively naive CD27 cells (Duddy 
et al., 2007). However, frequencies of CD27+ cells before 
depletion were similar between healthy controls and MS 
patients, and so elevated IL-6 in MS patients may not be 
solely attributed to the frequency of this subset. Future stud-
ies are aimed at identifying the IL-6–producing cells in 
humans. Whether this resetting of the B cell cytokine envi-
ronment will be lasting or short-lived still needs to be inves-
tigated. We suggest that measuring IL-6 production by B cells 
from patients might be a useful means for predicting (and 
monitoring) their response to BCDT.
The role of B cells in the generation and maintenance, but 
also control of pathogenic T cell responses in autoimmunity is a 
complex one that we have barely begun to understand. One 
issue is whether particular subsets of B cells have specific roles to 
play. However, in the area of regulation where most work has 
been done, there is a lack of clarity. The so-called B reg cells 
identified by some groups (e.g., B10 cells [Yanaba et al., 2008] 
or TN B cells [Blair et al., 2010]) may simply represent the most 
active IL-10 producers ex vivo; however, under stimulatory or 
inflammatory conditions other cells may come into play in vivo 
(e.g., MZ B cells, plasmablasts, or human memory-type cells 
[Barr et al., 2007; Lampropoulou et al., 2008; Bouaziz et al., 
2010; Neves et al., 2010]). In this study, we find that the very 
same cells, namely CD1dHi MZ B cells, can produce IL-6 and 
IL-10 upon short-term stimulation in vitro. Our data suggest 
that the same B cells might promote either pathogenesis or 
regulation depending on the prevailing immunological con-
text in which they find themselves (Gray and Gray, 2010; 
Lampropoulou et al., 2010). A possible scenario could be that in 
vivo the pathogenic (IL-6) and regulatory (IL-10) responses are 
generated with different kinetics as a result of stimuli dose varia-
tions or the combinatorial quality of the signals driving one or 
other response. Of particular note is the role of CD40 stimula-
tion in IL-6 and IL-10 production by B cells. IL-6 is augmented 
by CD40 stimulation, whereas IL-10 is inhibited. This suggests 
that B cells responding solely to TLRs become regulatory, 
whereas upon receiving T cell help B cells promote inflamma-
tion through secretion of IL-6. With human B cells, IL-10 may 
also augmented by CD40 stimulation (Burdin et al., 1995), and 
so it will be important to ascertain the stimuli that lead to IL-6 
expression in vivo. Thus we propose that B cells become inflam-
matory only upon interaction with appropriately primed helper 
T cells (i.e., late in the response) and regulatory in the absence 
of specific T cell help (i.e., early in the response).
With regard to the signals that drive different B cell cyto-
kine responses in vivo during disease induction no compre-
hensive study exists, the closest is a study published by Duddy 
et al. (2007) comparing patients with RR-MS and controls. 
production of IL-6 by B cells from MS patients was effectively 
normalized by Rituximab treatment. In both patients and 
mice the reduced disease severity after B cell depletion was 
accompanied by a decrease in the autoreactive Th17 response, 
and so we believe that B cells are making an all-important 
contribution to the IL-6–dependent promotion of pathogenic 
Th17 differentiation (Bettelli et al., 2006). The role of IL-17 in 
EAE/MS pathogenesis has undergone controversy (Komiyama 
et al., 2006; Haak et al., 2009) since the first observation 
(Bettelli et al., 2006); however, the current consensus is that 
Th17 as well as Th1 cells contribute to disease progression 
(Kroenke et al., 2008; O’Connor et al., 2008; Zepp et al., 
2011). We should also not forget that IL-6 has many other ac-
tions that contribute to pathology in autoimmune or chronic 
inflammatory conditions (Neurath and Finotto, 2011), but we 
do not know yet if B cell–derived IL-6 contributes more 
widely to pathogenesis than supporting the Th17 response. 
This seems likely, as IL-6 controls proliferation and resistance 
to apoptosis of activated T cells (Neurath and Finotto, 2011), 
it switches off the suppressive effects of T reg cells (Pasare and 
Medzhitov, 2003), and IL-6 blockade inhibits the develop-
ment of myelin-specific Th1 as well as Th17 cells in EAE 
(Serada et al., 2008). Of note, B cells can also secrete other 
proinflammatory cytokines in RR-MS (Duddy et al., 2007; 
Bar-Or et al., 2010), and it will be important to evaluate 
directly the pathogenic contribution of these functions to the 
disease process in future studies, even though our data clearly 
emphasize IL-6 as a major B cell–derived driver of disease.
Interestingly, the B cell IL-6 response does not influence 
the onset of EAE, suggesting a later acting role. The late con-
tribution of B cells to pathogenesis coincides with the expan-
sion of CD1dHi MZ B cells, the most potent producers of 
B cell–derived IL-6. In contrast, we have previously shown 
that the B cell IL-10 response and regulatory function is set up 
early during immune responses, in both autoimmune and in-
fection models (Lampropoulou et al., 2008; Barr et al., 2010; 
Neves et al., 2010). This early IL-10 response sets up the op-
portunity of a negative feed-forward loop, and this not only has 
the benefit of preventing excessive inflammation but also, sur-
prisingly, of accelerating the immune response (Lampropoulou 
et al., 2010; Neves et al., 2010). We have proposed that an 
impairment or lack of this early-acting B cell regulation is the 
reason why autoimmune activation leads to chronic non-
resolving lesions that progress to full-blown disease (Fillatreau 
et al., 2008). The prediction of an imbalance in the B cell 
cytokine response in autoimmune conditions is borne out by 
the observation that B cells from MS patients make less IL-10 
(Duddy et al., 2007). Another aspect of this imbalance can be 
seen here in MS patients compared with healthy volunteers 
and also in the patients after BCDT. The levels of IL-6 made 
by B cells from MS patients are much higher than from 
healthy volunteers and there is a dramatic fall to normal IL-6 
secretory activity after BCDT. This would suggest that the 
B cells repopulating after Rituximab are normal and have not 
been influenced by conditions that led to the pathogenic 
cytokine imbalance. In other words, the B cell cytokine 
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MATERIALS AND METHODS
Mice. Mice were bred and maintained in specific pathogen-free conditions 
at the School of Biological Sciences facility at the University of Edinburgh. 
Mice were aged 6–8 wk at the start of procedures. Experiments were cov-
ered by a UK Home Office Project License, granted under the Animal 
(Scientific Procedures) Act 1986 and approved locally by the University of 
Edinburgh Ethical Review Committee.
B cell subset sorting and stimulation. B cells were isolated by CD43 deple-
tion from spleens of naive or EAE day 14 mice, using MACS magnetic beads 
(Miltenyi Biotec). The negative fraction was stained with CD19, CD21, CD1d, 
and CD23, and then FACS sorted for MZ, FO, and double-negative TN popula-
tions. 5–10 × 105 cells were lysed in RNAZol for mRNA extraction and cDNA 
synthesis. 5 × 105 cells per well were stimulated with 5 µg/ml LPS or 10 µg/ml 
anti-CD40, in combination or alone. Controls cells were left unstimulated. 
Supernatants were harvested 24 or 72 h later. The following primers were used 
for RT-PCR: actin sense, 5-TGGAATCCTGTGGCATCCATGAAAC-3; 
actin antisense, 5-TAAAACGCAGCTCAGTAACAGTCC-3; IL-6 sense, 
5-GTTCTCTGGGAAATCGTGGA-3; IL-6 antisense, 5-TGTAC-
TCCAGGTAGCTATGG-3; IL-10 sense, 5-AGCCGGGAAGACAATA-
ACTG-3; and IL-10 antisense, 5-CATTTCCGATAAGGCTTGG-3.
Mixed bone marrow chimeras. Mice with a B cell–specific IL-6 deficiency 
were generated using the mixed bone marrow chimera system as described 
previously (Fillatreau et al., 2002; Barr et al., 2010). In brief, irradiated MT 
mice were reconstituted with a mixed inoculum of bone marrow (20% 
IL-6/ or WT and 80% MT). The hematopoietic compartment was left for 
8–10 wk to repopulate. Thus, all B cells arising from these inocula originated 
from the IL-6/ (or WT) portion, with all other hematopoietic lineages de-
riving predominantly from the MT portion (i.e., IL-6 sufficient). These mice 
were designated B-IL-6/ and B-WT chimeras. To control for a partial IL-6 
deficiency in the non–B cell compartment, a control group with a 20% defi-
ciency in all hematopoietic cells was made (designated IL-620%). Chimerism 
was confirmed by IL-6 ELISA on supernatants from MACS sorted B cell 
(CD43) and non–B cell compartments (CD43+) after PMA and ionomycin 
stimulation. Characterization of chimeras is outlined in Fig. 2 A.
Induction of EAE. Mice were immunized subcutaneously with 100 µg 
MOG (35–55) peptide emulsified in complete Freund’s adjuvant and 200 ng 
pertussis toxin (Ptx) intraperitoneally on day 0, as previously described (Fillatreau 
et al., 2002). Mice received a second dose of Ptx 2 d later. Clinical signs of EAE 
were assessed as follows: 0, no signs; 1, flaccid tail; 2, impaired gait/righting 
reflex; 3, partial hind limb paralysis; 4, total hind limb paralysis; 5, hind limb pa-
ralysis with partial front limb paralysis; 6, moribund or dead.
Mouse B cell depletion. The anti-CD20 antibody 18B12 and its isotype 
control (IgG2a) were provided by M. Kehry and R. Dunn (Biogen Idec, 
Weston, MA). B cells were depleted with a single 250 µg dose via the intra-
venous route at day 10. Depletion was confirmed by staining circulating 
CD19+ cells in blood taken 14–21 d after EAE induction.
Intracellular cytokine staining. Splenocytes from EAE mice were stimu-
lated with 10 ng/ml PMA and 1 µg/ml ionomycin (Sigma-Aldrich) in the 
presence of 1 µg/ml brefeldin A (GolgiStop; BD) for 4 h. Cells were washed 
in FACS buffer (PBS, 2% FCS, and 0.02% NaN3) and stained for CD4 (GK1.5; 
BioLegend). Samples were treated with fixative/permeabilization buffer (BD) 
and then stained with anti–IFN- (XMG1.2) and anti–IL-17 (TC11.18H10; 
BioLegend). Samples were acquired using FACSCanto and LSR-II flow 
cytometers (BD). Data were analyzed using FlowJo software (Tree Star).
In vitro restimulation assays. 106 cells/ml MACS-sorted CD4+ T cells 
from spleens of EAE mice were cultured with 30 µM–0.1 µM MOG pep-
tide. WT naive irradiated splenocytes were used as APC at a 1:1 ratio in 
a total volume of 200 µl. Supernatants were harvested after 3 d and cyto-
kine quantified by ELISA (BD) or BioPlex (Bio-Rad Laboratories) using 
Interestingly, they find that the IL-10 derives from naive 
B cells as opposed to activated/memory B cells, whereas the 
converse is true of the inflammatory cytokines such as TNF 
and lymphotoxin. This study of MS patients (Duddy et al., 
2007) used signals mimicking adaptive stimuli (anti-BCR and 
anti-CD40), and in mice with EAE, it is also true that 
the regulatory B cell IL-10 response required T cell–derived 
(CD40L) and antigen-specific signals (Fillatreau et al., 2002). 
However, the production of IL-10 in mice (Lampropoulou 
et al., 2008; Barr et al., 2010; Neves et al., 2010) and humans 
(Bouaziz et al., 2010) is strongly augmented by TLR signals 
and, indeed, these innate signals are required in vivo for the 
full expression of regulatory activity (Lampropoulou et al., 
2008; Neves et al., 2010) and T cell programming by B cells 
in general (Barr et al., 2010). We know less about the control 
of the B cell IL-6 response; however, it seems to mirror the 
IL-10 response in that it is elicited both by innate and adaptive 
stimuli and it is secreted most actively by cells within the 
same subpopulation (MZ). In the experiments shown here and 
in previous studies (Barr et al., 2007; Lampropoulou et al., 2008), 
anti-CD40 and TLR signals (LPS) synergize in their stimula-
tion of IL-6 secretion. Intriguingly, no signal has been iden-
tified that selectively instructs pro- or anti-inflammatory 
functions in B cells. We have previously shown that B cells 
activated via TLR produce a cytokine milieu that can inhibit 
T cell stimulation by dendritic cells (via IL-10) while facilitat-
ing T cell activation by anti-CD3 (via IL-6; Lampropoulou 
et al., 2008). Activated B cells can therefore concomitantly 
secrete cytokines having opposite effects on immune responses 
so that their net influence on immunity profoundly depends 
on their immediate cellular microenvironment, which is likely 
to change during the course of the immune response.
Our findings might be particularly relevant for treatment 
of RR-MS. Both IFN- and glatiramer acetate therapies in-
duce increased IL-10 secretion by B cells (Kala et al., 2010; 
Ramgolam et al., 2011), suggesting that part of their beneficial 
effects relates to tipping the balance from pathogenic to regula-
tory B cell function. IFN- has broader effects on cytokine 
production by B cells, reducing their secretion of IL-1  
and IL-23 while increasing expression of IL-12 and IL-27 
(Ramgolam et al., 2011), an activity likely to reduce Th17 dif-
ferentiation. Our study supports the notion that the pathogenic 
role for B cells in MS (and other autoimmune diseases) relates 
largely to their production of cytokines (Bar-Or et al., 2010). 
Here, we demonstrate that IL-6 production is a primary mech-
anism of B cell–mediated pathogenesis during EAE, and we 
provide evidence that this inflammatory pathway is profoundly 
deregulated in RR-MS. It will be important to evaluate 
whether current RR-MS therapies modulate the production 
of IL-6 by B cells during RR-MS. Remarkably, the repopulat-
ing B cells after BCDT no longer have a pathogenic cytokine 
profile, suggesting that the mode of action of such treatment 
relies on the elimination of inflammatory B cell activities. 
Novel approaches that selectively modulate cytokine produc-
tion by activated B cells might provide interesting alternatives 
to control pathogenic inflammation in autoimmune diseases.
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commercially available antibody sets for IL-6, IL-10, IL-17, and IFN- in 
accordance with the manufacturer’s instructions.
RR-MS patient study groups. All patients in this study were participants 
in the clinical trial program of Rituximab in MS and were subject to inclu-
sion criteria outlined previously. These include the phase II placebo con-
trolled study by Hauser et al. (2008) and the open-label phase I RR-MS 
study by Bar-Or et al. (2008). These placebo-controlled randomized trials 
were performed at 32 different centers in the United States and Canada. Pro-
tocols were approved by the institutional review board and the ethics reviews 
committee of each institution. For Fig. 5 A, there were five female (aged 26, 
28, 37, 51, and 66 yr) and three male (aged 27, 33, and 51 yr) patients, with 
the same number of age/sex-matched healthy control volunteers. For Fig. 5 B, 
there were seven female (aged 55, 42, 61, 41, 49, 52, and 39 yr) and five male 
(aged 51, 55, 59, 28, and 54 yr) patients. Patients were not HLA typed and 
were receiving no treatments other than Rituximab.
Rituximab treatment of RR-MS. Patients were given two infusions of 
1,000 mg Rituximab, 2 wk apart, and then followed prospectively. CD19+  
B cells were isolated from PBMC obtained from the patients before treatment 
with Rituximab and at 12 mo after treatment as outlined in the next section.
Human PBMC cultures. Human B cells and PBMC were isolated and 
stimulated as previously described (Duddy et al., 2007). In brief, after Ficoll-
Plaque separation and CD19+ MACS sorting, B cells were plated at 7.5 × 105 
cells/ml in a total volume of 200 µl. The cells were cultured with CD154-
transfected L cells together with anti-BCR (cross-linking anti-IgM/IgG), 
with and without the addition of CpG DNA. After 3 d, supernatants were 
harvested for cytokine analysis by ELISA. Cytokine production was assessed 
by ELISA using OptEIA ELISA kits (BD).
Adoptive transfer of DO11.10 T cells. T cells from spleens of pOVA-
specific transgenic mice (DO11.10) were sorted by CD4+ selection using 
MACS. 106 cells were injected intravenously into BALB/c or B cell– 
deficient hosts (JHD). Animals were immunized subcutaneously with 100 µg 
pOVA emulsified in CFA 24 h later. Animals were sacrificed 5 d after im-
munization, and cytokines were quantified in splenocytes by flow cytometry 
as outlined in Intracellular cytokine staining. Transferred T cells were identi-
fied using the anti-idiotype antibody KJ1.26.
Statistics. Student’s t test and Mann Whitney U test were used to calculate 
p-values between groups with normal and non-Gaussian distributions, 
respectively. Comparison between three or more groups was by one-way 
ANOVA with Bonferroni’s post-test analyses. Where comparing curves 
with two variables (e.g., time and disease score) two-way ANOVA was used. 
Survival curves were analyzed by log-rank test.
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